Dr. Hoenle AG (DE:HNL)
XETRA:HNL
HNL Stock Chart & Stats
€7.10
-€0.20(-2.86%)
At close: 4:00 PM EST
€7.10
-€0.20(-2.86%)
Day’s Range― - ―
52-Week Range€6.48 - €11.90
Previous CloseN/A
Volume3.05K
Average Volume (3M)6.13K
Market Cap
€53.10M
Enterprise Value€94.19M
Total Cash (Recent Filing)€6.71M
Total Debt (Recent Filing)€47.80M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding6,062,930
10 Day Avg. Volume3,193
30 Day Avg. Volume6,130
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)0.65
Price to Sales (P/S)0.53
P/FCF Ratio15.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)€100.27M
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationConsistent positive operating and free cash flow provide durable internal funding for working capital, product development and selective capex. This reduces reliance on external financing, improves resilience through industry cycles, and supports reinvestment into recurring after‑sales and measurement offerings.
Diversified Industrial Revenue StreamsMultiple product lines (systems, disinfection, instrumentation, lamps/glass) create cross‑selling opportunities and recurring aftermarket revenue from consumables and replacements. This breadth reduces dependence on a single market, smoothing cash flows and enhancing long‑term customer stickiness.
Manageable LeverageModest debt relative to equity provides financial flexibility to fund growth or weather downturns without excessive refinancing risk. With positive cash flow, the company can service obligations while preserving room to invest in product development and international sales expansion.
Bears Say
Persistent Net LossesOngoing net losses and negative operating income indicate the company has not yet converted revenue growth into sustainable profits. Continued losses constrain retained earnings, limit R&D/marketing budgets, and may force reliance on external capital if cash generation weakens.
Negative Return On EquityA negative ROE signals that invested equity is not generating returns for shareholders, reflecting persistent earnings deficits. This can hinder the company’s ability to attract equity investment, increase the cost of capital, and pressure management to restore profitability.
Exposure To Cyclical Capex DemandRevenue and order activity are tied to industrial capital expenditure cycles, making demand lumpy and sensitive to macro and industry capital budgets. This structural cyclicality raises forecasting uncertainty and can amplify margin pressure during downturns despite aftermarket resilience.
Dr. Hoenle AG News
HNL FAQ
What was Dr. Hoenle AG’s price range in the past 12 months?
Dr. Hoenle AG lowest stock price was €6.48 and its highest was €11.90 in the past 12 months.
What is Dr. Hoenle AG’s market cap?
Dr. Hoenle AG’s market cap is €53.10M.
When is Dr. Hoenle AG’s upcoming earnings report date?
Dr. Hoenle AG’s upcoming earnings report date is May 19, 2026 which is in 43 days.
How were Dr. Hoenle AG’s earnings last quarter?
Dr. Hoenle AG released its earnings results on Feb 24, 2026. The company reported -€0.25 earnings per share for the quarter, missing the consensus estimate of -€0.217 by -€0.033.
Is Dr. Hoenle AG overvalued?
According to Wall Street analysts Dr. Hoenle AG’s price is currently Overvalued.
Does Dr. Hoenle AG pay dividends?
Dr. Hoenle AG pays a Annually dividend of €0.2 which represents an annual dividend yield of N/A. See more information on Dr. Hoenle AG dividends here
What is Dr. Hoenle AG’s EPS estimate?
Dr. Hoenle AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dr. Hoenle AG have?
Dr. Hoenle AG has 6,062,930 shares outstanding.
What happened to Dr. Hoenle AG’s price movement after its last earnings report?
Dr. Hoenle AG reported an EPS of -€0.25 in its last earnings report, missing expectations of -€0.217. Following the earnings report the stock price went up 6.54%.
Which hedge fund is a major shareholder of Dr. Hoenle AG?
Currently, no hedge funds are holding shares in DE:HNL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Hoenle AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.44%
12-Months-Change
Fundamentals
Return on Equity
-5.31%
Trailing 12-Months
Asset Growth
-7.47%
Trailing 12-Months
Company Description
Dr. Hoenle AG
Dr. Hönle AG supplies industrial UV technologies and systems in Germany and internationally. The company operates through three segments: Adhesives, Equipment & Systems, and Glass & Lamps. The Adhesives segment provides industrial adhesives for applications, such as consumer electronics, medical technology, optics and opto electronics, automotive, and glass processing. The Equipment & Systems segment engages in the drying of inks and coatings, curing of adhesives and plastics, disinfecting surfaces, and solar simulation. The Glass & Lamps segment offers quartz glass tubing and rods for the lamp, automotive, semiconductor, and fibre cable industries, as well as lamps for water disinfection, and the drying of coatings and adhesives. The company was founded in 1976 and is headquartered in Munich, Germany.
Technical Analysis
LPKF Laser & Electronics
―
Manz AG
―
MAX Automation
―
Singulus Technologies
―
Suss Microtec
―
Options Prices
Currently, No data available
---